Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies for cancer and autoimmune diseases. The U.S. FDA approved AUCATZYL (obecabtagene autoleucel, also known as obe-cel) in November 2024 for adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). Commercial launch and first sale of AUCATZYL in the United States occurred in January 2025, generating $74.3 million in net product revenue for the year ended December 31, 2025. The United Kingdom MHRA granted AUCATZYL conditional marketing authorization in April 2025, and NICE recommended its use in the NHS in November 2025, leading to a UK launch in January 2026. The European Commission granted marketing authorization for AUCATZYL in July 2025 for adult r/r B-ALL (age 26 and older), but the EU launch is currently on hold with no EU sales anticipated in 2026. Obe-cel is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy, manufactured at the company's Nucleus facility in Stevenage, U.K., which obtained MIA and GMP certificates in March 2024 and has a capacity for approximately 2,500 batches annually. Preliminary data from the Phase 1b CATULUS trial of obe-cel in pediatric r/r B-ALL and B-NHL, presented in December 2025, showed a 95.5% overall response rate (ORR) and 90.9% complete response (CR), with low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obe-cel for pediatric r/r B-ALL in October 2025. Phase 1 CARLYSLE trial data for obe-cel in severe, refractory systemic lupus erythematosus (SLE), presented in December 2025, showed deep, durable responses and B-cell depletion with no ICANS or high-grade CRS. Obe-cel has advanced into a Phase 2 potentially pivotal LUMINA study for severe, refractory lupus nephritis (LN), which is now enrolling, and a Phase 1 dose escalation clinical trial for progressive multiple sclerosis (MS) initiated in October 2025. AUTO1/22, a dual-targeting CAR T, showed 83% MRD negative complete remissions in a Phase 1 pediatric ALL trial, with no antigen-negative relapse observed. AUTO8, a next-generation product candidate for multiple myeloma and AL amyloidosis, demonstrated 100% ORR in a Phase 1 multiple myeloma trial, with 7 CR/sCR and no Grade 3 ICANS or CRS. The first patient was dosed in the Phase 1 ALARIC trial for AUTO8 in light-chain amyloidosis in October 2025. A Phase 1 clinical trial of AUTO6NG in r/r neuroblastoma was initiated in December 2023 and is currently enrolling patients. The company reported a net loss of $287.5 million for the year ended December 31, 2025, compared to $220.7 million for 2024, with an accumulated deficit of $1,386.8 million. Net cash used in operating activities increased to $283.6 million in 2025 from $206.3 million in 2024. Strategic financing agreements include a final $30 million payment from Blackstone in December 2024 and a $250 million aggregate payment from BioNTech in February 2024, which included a $200 million equity investment and $50 million in upfront payments for licenses and revenue interest. The company paid $2.8 million in revenue share to Blackstone and $1.5 million to BioNTech in 2025. A $1.0 million clinical milestone payment was received from Moderna in 2025. Regulatory milestone payments of £10.0 million (FDA approval) and £6.0 million (EC approval) were paid to UCLB for AUCATZYL. The company had $104.1 million in cash and cash equivalents and $196.6 million in marketable securities as of December 31, 2025. Total full-time employees increased to 752 as of December 31, 2025, from 647 in 2024.